Improve cognition through aerobic exercise
- Trial ID
- NCT07299279
- Official Title
- Movement Improves Brain Health and Cognition in Parkinson's Disease
- Goal
- Improve cognition through aerobic exercise
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Study Type
- INTERVENTIONAL
- Enrollment
- 150 participants
- Conditions
- Parkinson Disease
- Interventions
- Aerobic exercise for >_75 minutes/week of vigorous aerobic exercise or >_ 150 minutes/week of moderate aerobic exercise in at least two weekly sessions, for 12 m
Plain-Language Summary
The goal is to find out whether a year of regular aerobic exercise can improve brain health and cognitive function in people with Parkinson’s who have mild cognitive impairment. Participants will do either more than 75 minutes per week of vigorous aerobic activity or more than 150 minutes per week of moderate aerobic activity in at least two weekly sessions for 12 months, with the idea that higher heart rate and blood flow boost protective growth factors like BDNF, support neuroplasticity, and work alongside usual Parkinson’s medications rather than replace them. The trial is looking for people aged 30 to 80 with PD at Hoehn and Yahr stages 1,3 who meet MDS level II criteria for PD-MCI, are not already exercising above the study thresholds, can safely do vigorous exercise, and can give informed consent.
Locations
- Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Rome, Italy
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Aerobic exercise for >_75 minutes/week of vigorous aerobic exercise or >_ 150 minutes/week of moderate aerobic exercise in at least two weekly sessions, for 12 m. The goal is to find out whether a year of regular aerobic exercise can improve brain health and cognitive function in people with Parkinson’s who have mild cognitive impairment. Participants will do either more than 75 minutes per week of vigorous aerobic activity or more than 150 minutes per week of moderate aerobic activity in at least two weekly sessions for 12 months, with the idea that higher heart rate and blood flow boost protective growth factors like BDNF, support neuroplasticity, and work alongside usual Parkinson’s medications rather than replace them. The trial is looking for people aged 30 to 80 with PD at Hoehn and Yahr stages 1,3 who meet MDS level II criteria for PD-MCI, are not already exercising above the study thresholds, can safely do vigorous exercise, and can give informed consent.
- Who can participate?
- Participants must be between 30 Years and 80 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 2 years and 11 months.